FY2025 EPS Estimates for Korro Bio Boosted by HC Wainwright

Korro Bio, Inc. (NASDAQ:KRRO) – HC Wainwright lifted their FY2025 earnings per share (EPS) estimates for Korro Bio in a research note issued to investors on Thursday, November 13th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($9.24) per share for the year, up from their previous estimate of ($9.93). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Korro Bio’s current full-year earnings is ($9.52) per share. HC Wainwright also issued estimates for Korro Bio’s Q4 2025 earnings at ($2.08) EPS, Q1 2026 earnings at ($1.86) EPS, Q2 2026 earnings at ($1.67) EPS, Q3 2026 earnings at ($1.71) EPS, Q4 2026 earnings at ($1.75) EPS and FY2026 earnings at ($6.99) EPS.

A number of other analysts have also recently commented on KRRO. Royal Bank Of Canada cut Korro Bio from an “outperform” rating to a “sector perform” rating in a research report on Thursday. William Blair lowered Korro Bio from an “outperform” rating to a “market perform” rating in a research note on Thursday. Cantor Fitzgerald lowered Korro Bio from an “overweight” rating to a “neutral” rating in a research report on Thursday. Raymond James Financial downgraded Korro Bio from a “strong-buy” rating to a “market perform” rating in a report on Thursday. Finally, Wall Street Zen upgraded shares of Korro Bio from a “sell” rating to a “hold” rating in a research note on Saturday. One analyst has rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $76.00.

Korro Bio Stock Down 6.6%

Shares of NASDAQ:KRRO opened at $6.07 on Monday. The company’s fifty day moving average is $37.71 and its 200 day moving average is $23.47. Korro Bio has a 52 week low of $5.70 and a 52 week high of $56.69. The stock has a market cap of $57.18 million, a PE ratio of -0.65 and a beta of 2.94.

Korro Bio (NASDAQ:KRRO) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($1.92) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.61) by $0.69. Korro Bio had a negative return on equity of 68.87% and a negative net margin of 1,199.53%.The company had revenue of $1.09 million for the quarter, compared to the consensus estimate of $0.41 million.

Institutional Investors Weigh In On Korro Bio

Large investors have recently bought and sold shares of the stock. Quarry LP acquired a new stake in Korro Bio during the 1st quarter worth $35,000. Russell Investments Group Ltd. purchased a new stake in Korro Bio during the 3rd quarter valued at approximately $39,000. CWM LLC grew its stake in shares of Korro Bio by 391.4% in the 3rd quarter. CWM LLC now owns 2,693 shares of the company’s stock valued at $129,000 after purchasing an additional 2,145 shares during the last quarter. PNC Financial Services Group Inc. purchased a new position in Korro Bio in the 3rd quarter valued at $140,000. Finally, AlphaQuest LLC raised its position in Korro Bio by 320.1% during the 1st quarter. AlphaQuest LLC now owns 9,196 shares of the company’s stock worth $160,000 after buying an additional 7,007 shares during the last quarter. Hedge funds and other institutional investors own 13.18% of the company’s stock.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).